Hangzhou Tigermed Consulting Co., Ltd 300347.SZ

CN · XSHE · XSHE · stock · Healthcare · website

Hangzhou Tigermed Consulting Co., Ltd financials (annual)

Revenue

Net income

Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥6.8B	CN¥6.6B	CN¥7.4B	CN¥7.1B
Gross profit	CN¥1.9B	CN¥2.2B	CN¥2.8B	CN¥2.8B
R&D expense	CN¥257.6M	CN¥238.4M	CN¥261.6M	CN¥234.6M
SG&A expense	CN¥322.2M	CN¥349.3M	CN¥306.7M	CN¥292.5M
Operating income	CN¥666.6M	CN¥1.1B	CN¥1.8B	CN¥1.8B
Interest expense	CN¥90.6M	CN¥141.2M	CN¥119.9M	CN¥83.2M
Income tax	CN¥198.2M	CN¥216.6M	CN¥338.6M	CN¥313.7M
Net income	CN¥887.9M	CN¥405.1M	CN¥2.0B	CN¥2.0B
EPS (diluted)	CN¥1.04	CN¥0.47	CN¥2.34	CN¥2.32
Operating cash flow	CN¥1.1B	CN¥1.1B	CN¥1.2B	CN¥1.4B
Free cash flow	CN¥903.7M	CN¥740.4M	CN¥836.7M	CN¥908.9M
Cash & equivalents	CN¥1.8B	CN¥2.1B	CN¥7.4B	CN¥7.9B
Inventory	CN¥41.5M	CN¥32.0M	CN¥23.4M	CN¥22.2M
Goodwill	CN¥3.5B	CN¥3.2B	CN¥2.8B	CN¥2.5B
Total assets	CN¥28.4B	CN¥28.7B	CN¥29.7B	CN¥27.4B
Total debt	CN¥1.7B	CN¥2.8B	CN¥3.4B	CN¥2.8B
Total liabilities	CN¥4.1B	CN¥4.6B	CN¥5.2B	CN¥4.8B
Shareholders' equity	CN¥21.0B	CN¥20.7B	CN¥21.0B	CN¥19.6B

Growth · year-over-year · Revenue CAGR -1.2%

Metric	FY2025	FY2024	FY2023	FY2022
Revenue growth	+3.5%	-10.6%	+4.2%	—
Net income growth	+119.2%	-80.0%	+0.9%	—
EPS growth	+121.3%	-79.9%	+0.9%	—
Free cash flow growth	+22.0%	-11.5%	-7.9%	—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.